

## AMENDMENTS TO THE CLAIMS:

The following claim listing will replace all previous listings of the claims:

1. – 10. (Cancelled)

11. (Currently amended) A method for down-regulating the immuno-activity of [[a]] an immune-competent bone-marrow graft comprising bone marrow stem cells in a subject, said method comprising administering to said subject an effective amount of a monoclonal antibody against CD83, or an antigen-binding fragment thereof for a time and under conditions sufficient to inhibit or otherwise down-regulate one or more functional activities of a DC and/or T-cell by inducing cell lysis, wherein the monoclonal antibody or antigen-binding fragment thereof is not conjugated to a toxic component which induces or otherwise facilitates lysis of the DC and/or T cell.

12. (Currently Amended) A method for the prophylactic and/or therapeutic treatment of a condition characterized by the aberrant, unwanted or otherwise inappropriate immuno-activity of an immuno-competent ~~bone-marrow~~ graft comprising bone marrow stem cells in a subject, said method comprising contacting said graft with an effective amount of an antibody or an antigen-binding fragment thereof, which couples, binds or otherwise associates with a myeloid DC's and/or a T cell's surface activation CD83 molecule, for a time and under conditions sufficient to inhibit or otherwise down-regulate the immuno-activity of said DC and/or T cell by inducing cell lysis, wherein the antibody or antigen-binding fragment thereof is not conjugated to a toxic component which induces or otherwise facilitates lysis of the DC and/or T cell.

13. (Currently Amended) The method of claim 12 wherein the ~~bone-marrow~~ graft comprises allogenic bone marrow cells.

14. (Cancelled)

15. (Currently Amended) A method for the prophylactic and/or therapeutic treatment of a condition characterized by the aberrant, unwanted or otherwise inappropriate immuno-activity of [[a]] an immune-competent bone-marrow graft comprising bone marrow stem cells in a subject,

said method comprising contacting said graft with an effective amount of an antibody or an antigen-binding fragment thereof, which couples, binds or otherwise associates with a myeloid DC's and/or a T cell's CD83 molecule derived from said graft, for a time and under conditions sufficient to inhibit or otherwise down-regulate said inappropriate immuno-activity of said graft by inducing cell lysis, wherein the antibody or antigen-binding fragment thereof is not conjugated to a toxic component which induces or otherwise facilitates lysis of the DC and/or T cell.

16.-18. (Cancelled)

19. (Previously Presented) The method of claim 15 wherein the graft is an allogeneic bone marrow graft.

20.-22. (Cancelled)

23. (Currently Amended) The method of claim 11 wherein the ~~bone marrow~~ graft is an allogeneic bone marrow graft.

24. (New) The method of claim 12 wherein the graft is an allogeneic bone marrow graft.

25. (New) The method of claim 11 wherein the graft is an allograft comprising bone marrow stem cells.

26. (New) The method of claim 12 wherein the graft is an allograft bone marrow stem cells.

27. (New) The method of claim 15 wherein the graft is an allograft comprising bone marrow stem cells.